Literature DB >> 22056006

A model to predict mortality following Pseudomonas aeruginosa bacteremia.

Elizabeth B Hirsch1, Jessica M Cottreau, Kai-Tai Chang, Juan-Pablo Caeiro, Michael L Johnson, Vincent H Tam.   

Abstract

Infections caused by Pseudomonas aeruginosa are associated with significant mortality. Existing mathematical models identifying mortality risk factors lack validation. We developed and validated a model to predict mortality in patients with P. aeruginosa bacteremia. Risk factors for 30-day mortality were examined through multivariate logistic regression in 114 patients. Independent predictors of mortality included isolation of a multidrug-resistant strain, APACHE II ≥ 23, and age ≥ 65 years. Clonality was assessed for multidrug-resistant isolates. Predicted probability of 30-day mortality was validated in 49 patients, after conditioning the model by the identified risk factors. The patients were split into 'high-risk' and 'low-risk' groups based on model-predicted mortality; the observed/expected ratios were 1.21 and 1.92, respectively. Our model was reasonable in predicting 30-day mortality in patients with P. aeruginosa bacteremia. Our results may be useful for developing strategies to reduce mortality attributed to P. aeruginosa.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22056006     DOI: 10.1016/j.diagmicrobio.2011.09.018

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  6 in total

1.  Effectiveness and Safety of Beta-Lactam Antibiotics with and without Therapeutic Drug Monitoring in Patients with Pseudomonas aeruginosa Pneumonia or Bloodstream Infection.

Authors:  Ashlan J Kunz Coyne; Mohammad Alshaer; Anthony M Casapao; Veena Venugopalan; Carmen Isache; Jason Ferreira; Christopher A Jankowski
Journal:  Antimicrob Agents Chemother       Date:  2022-09-08       Impact factor: 5.938

2.  Time above the MIC of Piperacillin-Tazobactam as a Predictor of Outcome in Pseudomonas aeruginosa Bacteremia.

Authors:  Elias Tannous; Shelly Lipman; Antonella Tonna; Emma Hector; Ziad Hussein; Michal Stein; Sharon Reisfeld
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

3.  Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia.

Authors:  Dana R Bowers; Yi-Xin Liew; David C Lye; Andrea L Kwa; Li-Yang Hsu; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2012-12-21       Impact factor: 5.191

4.  Effect of metallo-β-lactamase production and multidrug resistance on clinical outcomes in patients with Pseudomonas aeruginosa bloodstream infection: a retrospective cohort study.

Authors:  Matthias Willmann; Ines Kuebart; Matthias Marschal; Klaus Schröppel; Wichard Vogel; Ingo Flesch; Uwe Markert; Ingo B Autenrieth; Florian Hölzl; Silke Peter
Journal:  BMC Infect Dis       Date:  2013-11-01       Impact factor: 3.090

5.  Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study.

Authors:  Ting-Yi Su; Jung-Jr Ye; Chien-Chang Yang; Ching-Tai Huang; Ju-Hsin Chia; Ming-Hsun Lee
Journal:  Ann Clin Microbiol Antimicrob       Date:  2017-07-24       Impact factor: 3.944

6.  Clinical outcomes, molecular epidemiology and resistance mechanisms of multidrug-resistant Pseudomonas aeruginosa isolated from bloodstream infections from Qatar.

Authors:  Mazen A Sid Ahmed; Jemal M Hamid; Ahmed A Husain; Hamad Abdel Hadi; Sini Skariah; Ali A Sultan; Emad Bashir Ibrahim; Abdul Latif Al Khal; Bo Soderquist; Jana Jass; Ali S Omrani
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.